Absence of proper treatment for brain cancer leads to the development of new drugs

Mumbai, India – May 5, 2014 - Inspite of the continual investments and research on brain cancer, the brain cancer with glioblastoma multiforme, continues to remain as one of the most deadly diseases in the developed world. The primary brain tumors are relatively rare and the chances of survival of patients with this condition are found to be rarer. Even though some of the best treatment options are available, only 205 pharmaceutical companies are currently targeting new drugs that treat the cancer.

At present, only 5% of the patients diagnosed with glioblastoma multiforme cancer survive more than three years, while for most, the life expectancy is reduced to 15 months even with the implementation of aggressive therapies. Brain Cancer statistics reveal that this aggressive form of cancer is incurable and therefore most of the pharmaceutical companies are now searching for ways that will make identifying of the vulnerabilities easier.

The ongoing brain cancer research has shown that the available drugs in the current markets do not satisfy the needs that exist in the brain tumor conditions, giving rise to the potential for the development of pipeline drugs that come with the capabilities of improving the quality of life and increasing the chances of survival. Today, as the patients are more aware of the latest technological advancements, some of the key factors that are driving the growth of the sector are the demand for drugs with increased efficacy, safety and tolerability. However, majority of the products in development are first class therapies that come with superior therapeutic performance, which further increases the challenge of the existing markets since pharmaceutical companies find it more and more difficult to maintain their market shares.

Though chemotherapy does work for some forms of brain tumor, it comes with its own share of side effects. Other than the major pharmaceutical companies, the brain cancer market also has engineers and neurosurgeons who are creating biodegradable nanoparticles that carry DNA-death genes to brain cancer cells that selectively kill them without affecting the normal brain tissue. Besides this, biotechnologists have also identified molecules, mainly the Vacquinol-1, that comes with the capability of killing the cancerous cells without any form of invasive surgery.

[b]For further insights,[/b] http://bit.ly/brain-cancer-2014

[b]About Research on Global Markets[/b]

Research on Global Markets is a leading source for market research on various sectors globally, offering premium research content from worldwide publishers of market research reports. Our database hosts premium market research content developed by global publishers. It offers premium industry research reports, company profiles and country briefs. We have a dedicated team of research professionals who can facilitate, in an unbiased manner, the process of identifying appropriate market research reports that are targeted to fulfill all your information-related requirements.

For more details on the content of each report and ordering information please contact:

[b]Phone:[/b] US/CAN: +1 800 986 6819
UK: +44 203 514 2363
India: +91 22 4098 7600
[b]E-Mail: [/b][email protected]
[b]Related links:[/b] www.blog.researchonglobalmarkets.com